Identification of Neoatherosclerosis in ISR Patients Based on Artifical Intelligence

Sponsor
Chinese PLA General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04220437
Collaborator
(none)
90
1
72.9
1.2

Study Details

Study Description

Brief Summary

Based on the large population of patients, in-stent restenosis (ISR) is still an important problem in the field of cardiovascular disease. How to reduce the incidence of ISR and the treatment of ISR has become the focus and hot spot. The 2018 ESC Guidelines for Cardiovascular Intervention recommends treatment of ISR under the guidance of intravascular ultrasound (IVUS), or optical coherent tomography (OCT). Circulation published a new Waksman ISR classification based on mechanisms and components of the restenosis tissue, which provides guidance for treatment strategy. Because of its good resolution, OCT makes it more accurate to distinguish the components of vascular tissue, thus providing a decision-making basis for interventional therapy. OCT examination can obtain the characteristics of the ISR more precisely. Neoatherosclerosis (NA), is one of the ISR types and accounts for more stent failure and target lesion failure than other types. Identification NA is important for decision-making of interventional therapy. However, the acquisition and analysis of OCT images not only need the digital angiography machine (DSA) equipped with the majority of hospitals, but also need professional OCT imaging equipment and technicians. Patients with severely CKD cannot bear OCT examination because of the large amount of contrast agent. OCT catheter is more than ten times the price of the CAG catheter. Therefore, identification of NA by the use of artificial intelligence (AI) is of significance to set therapeutic strategy for ISR patients, especially in patients with CKD. Our study retrospectively analyzed CAG images and OCT images of ISR patients obtained from Jan 1st,2015 to Oct 31st,2020. Identify NA by analyzing OCT images, build up U-net and V-net to analyze the CAG and OCT images, and finally build up an identification system of NA based on CAG images by AI. This study has been approved by Ethics Committee of Chinese PLA General Hospital (S2018-033-01)

Condition or Disease Intervention/Treatment Phase
  • Other: no interventin

Detailed Description

Drug Eluting Stents (DES) reduce the rate of in-stent restenosis (ISR) to 3.6-10%. Based on the large population of patients, ISR is still an important problem in the field of cardiovascular disease. How to reduce the incidence of ISR and the treatment of ISR has become the focus and hot spot. The 2018 ESC Guidelines for Cardiovascular Intervention recommends treatment of ISR under the guidance of intravascular ultrasound (IVUS), or optical coherent tomography (OCT). The European Expert Consensus on Intravascular Imaging, published in 2018, recommends finding the underlying mechanisms of ISR through intravascular imaging guidance (IVUS or OCT), and determining therapeutic strategies based on the mechanisms. Circulation published a new Waksman ISR classification based on mechanisms and components of the restenosis tissue, which provides guidance of treatment strategy. The use of intravascular imaging to identify and classify the types and mechanisms is very important for ISR treatment strategy. Because of its good resolution, OCT makes it more accurate to distinguish the components of vascular tissue, thus providing a decision-making basis for interventional therapy. OCT examination can obtain the characteristics of ISR more precisely. Neoatherosclerosis (NA), is one of the ISR types and accounts for more stent failure and target lesion failure than other types. Identification of NA is important for decision-making of interventional therapy. However, the acquisition and analysis of OCT images not only need the digital angiography machine (DSA) equipped with the majority of hospitals, but also need professional OCT imaging equipment and technicians. Patients with severely CKD cannot bear OCT examination because of the large amount of contrast agent. OCT catheter is more than ten times the price of the CAG catheter. Therefore, identification of NA by the use of artificial intelligence (AI) is of significance to set therapeutic strategy for ISR patients, especially in patients with CKD. Our study retrospectively analyzed CAG images and OCT images of ISR patients obtained from Jan 1st,2015 to Jan 31st,2020. Offline OCT analysis was performed using dedicated software (Light Lab Imaging Inc, Westford, MA). All images were analyzed at every frame in the stents by 2 independent investigators, who were blinded to the angiographic and clinical findings. Identify NA by analyzing OCT images, build up U-net and V-net to analyze the CAG and OCT images, and finally build up an identification system of NA based on CAG images by AI. This study has been approved by Ethics Committee of Chinese PLA General Hospital (S2018-033-01)

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Identification of Neoatherosclerosis in In-stent Restenosis Patients Based on Artifical Intelligence
Actual Study Start Date :
Feb 1, 2015
Anticipated Primary Completion Date :
Jan 31, 2021
Anticipated Study Completion Date :
Feb 28, 2021

Arms and Interventions

Arm Intervention/Treatment
CAG and OCT group

Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.

Other: no interventin
Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.

Outcome Measures

Primary Outcome Measures

  1. The identification of NA [through the study completion, an average of 3 years]

    a neointima containing a diffuse border and a signal-poor region, with the struts underneath invisible because of the marked signal attenuation

  2. neovascularizaion [through the study completion, an average of 3 years]

    diameter 50-300um, cavity in the stent area, not connected with the vasular

  3. ISR segment in the CAG images [through the study completion, an average of 3 years]

    the segement in the stent area or within 5mm beside the stent,diameter stenosis rate>50%

  4. lipid-core arc [through the study completion, an average of 3 years]

    To quantify the circumferential extent of NA, the lipid-core arc was measured at a 0.2-mm interval throughout the segments showing NA.

  5. Thin-cap fibroatheroma-like neointima [through the study completion, an average of 3 years]

    defined as a neointima characterized by a fibrous cap thickness at the thinnest part of <65 μm and an angle of lipid-laden neointima of >180 degrees

  6. macrophage arc [through the study completion, an average of 3 years]

    measured at 0.2-mm intervals and divided into 5 groups: grade 0, no macrophages; grade 1, localized macrophage accumulation, <30 degrees; grade 2, clustered accumulation, ≥30 and <90 degrees; grade 3, clustered accumulation, ≥90 and <270 degrees; and grade 4, clustered accumulation, ≥270 degrees.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • all gender

18ys old to 80ys old

diagnosed of in-stent restenosis based on CAG

both CAG images and OCT images were obtained in the same patient on the same day

Exclusion Criteria:
  • CAG images and OCT images were not obtained on the same day in the same patient

low quality in CAG images

low qualitiy in OCT images

Contacts and Locations

Locations

Site City State Country Postal Code
1 The General Hospital of PLA Beijing China 100853

Sponsors and Collaborators

  • Chinese PLA General Hospital

Investigators

  • Principal Investigator: Yundai Chen, M.D, Chinese PLA General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yun Dai Chen, Professor, Chinese PLA General Hospital
ClinicalTrials.gov Identifier:
NCT04220437
Other Study ID Numbers:
  • AI-301-ISR
First Posted:
Jan 7, 2020
Last Update Posted:
Jan 15, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yun Dai Chen, Professor, Chinese PLA General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 15, 2021